Navigation Links
Valeant Extends Offer To Acquire Allergan
Date:8/15/2014

be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," "opportunity," "tentative," "positioning," "designed," "create," "predict," "project," "seek," "ongoing," "upside," "increases" or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to numerous assumptions, risks and uncertainties that change over time and could cause actual results to differ materially from those described in the forward-looking statements.  These assumptions, risks and uncertainties include, but are not limited to, assumptions, risks and uncertainties discussed in the company's most recent annual or quarterly report filed with the SEC and the Canadian Securities Administrators (the "CSA") and assumptions, risks and uncertainties relating to the proposed merger, as detailed from time to time in Valeant's filings with the SEC and the CSA, which factors are incorporated herein by reference.  Important factors that could cause actual results to differ materially from the forward-looking statements we make in this communication are set forth in other reports or documents that we file from time to time with the SEC and the CSA, and include, but are not limited to:

  • the ultimate outcome of the offer and the second-step merger, including the ultimate removal or the failure to render inapplicable the obstacles to consummation of the offer and the second-step merger described in the offer to exchange;
  • the ultimate outcome and results of integrating the operations of Valeant and Allergan, the ultimate outcome of Valeant's pricing and operating strategy applied to Allergan and the ultimate ability to realize synergies;
  • the effects of the proposed combination of Valeant and Allergan, including the combined company's future financial condition, operating r
    '/>"/>

  • SOURCE Valeant Pharmaceuticals International, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
    2. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
    3. Valeant Pharmaceuticals To Host Investor Day
    4. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
    5. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
    6. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
    7. Valeant Pharmaceuticals Announces Management Change
    8. Valeant Pharmaceuticals To Syndicate Incremental Loans
    9. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
    10. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
    11. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/29/2015)... , July 27, 2015 Research ... addition of the "Global Neurostimulation Devices Market ... The analysts forecast the global neurostimulation devices market ... the period 2014-2019. The report, Global ... on an in-depth market analysis with inputs from ...
    (Date:7/29/2015)... , July 29, 2015 The Judicial Panel ... week about whether to centralize Inferior vena cava (IVC) ... IVC manufacturer, Cook Medical, have already been centralized by ... implanted in patients at risk for a pulmonary embolism. ... traveling to the lungs. Claims against Bard and Cook ...
    (Date:7/29/2015)... , July 29, 2015  ViaCyte, Inc., a privately-held regenerative ... the treatment of diabetes in clinical trials, today announced the opening ... ONE, or S afety, T olerability, and E ... Diabetes.  The new site, which is the first in ... Hospitals in Edmonton , Alberta.  ...
    Breaking Medicine Technology:Global Neurostimulation Devices Market 2015-2019 2IVC filter litigation continues; law firm provides free information to IVC filter patients 2ViaCyte Announces Second Clinical Trial Site at University of Alberta 2ViaCyte Announces Second Clinical Trial Site at University of Alberta 3ViaCyte Announces Second Clinical Trial Site at University of Alberta 4
    ... - Poster Presented at ASCO Annual Meeting ... CHICAGO, May 31 /PRNewswire-FirstCall/,-- Poniard Pharmaceuticals, Inc. ... on oncology, today presented preliminary safety and,efficacy ... trial of picoplatin in,combination with docetaxel and ...
    ... 3 Study Presented at ASCO -, COLLEGEVILLE, ... Wyeth (NYSE: WYE ), today announced results,of ... patients with relapsed,and/or refractory mantle cell lymphoma (MCL), ... (mammalian target of rapamycin) inhibitor,TORISEL(R) (temsirolimus) experienced a ...
    Cached Medicine Technology:Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer 2Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer 3Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer 4New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 2New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 3New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 4New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 5New Data Show TORISEL Improves Progression-Free Survival for Patients With Relapsed/Refractory Mantle Cell Lymphoma 6
    (Date:7/29/2015)... ... July 29, 2015 , ... More than ... service providers of children living with autism will converge upon Penn State to ... , The National Autism Conference will be held Aug. 3-6 at the ...
    (Date:7/29/2015)... ... July 29, 2015 , ... According to The Spirits Business on ... directly responsible for stimulating and perpetuating alcohol use disorders. Humans have the same gene, ... the National academy of Sciences, and has given researchers inklings to explore Rsu1 in ...
    (Date:7/29/2015)... ... 2015 , ... With a new community program in the ... Support Services and announced a new charity campaign to raise funds to support ... workshops and educational programs at no charge. Scott Campbell Agency initiates this ...
    (Date:7/29/2015)... New York, NY (PRWEB) , ... July 29, 2015 , ... Wedding season is in ... wedding bells comes the extra pressure of looking good on the big day. Every bride ... pre-wedding prep to a new level. , According to a recent study ...
    (Date:7/29/2015)... , ... July 29, 2015 , ... ... the Hackett Hemwall Foundation in March, Steven W. Meier M.D., a prominent orthopedic ... treatments to qualifying patients with demonstrated financial need. , “We are thrilled for ...
    Breaking Medicine News(10 mins):Health News:Penn State Conference to Address Instruction, Success for Children with Autism 2Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 2Health News:Study Reveals Potential for Gene Manipulation to Stop Alcohol Addiction 3Health News:Scott Campbell Agency and Nonprofit Stillwaters Cancer Support Services Initiate New Charity Campaign in Waukesha, WI to Provide Help for People Touched by Cancer 2Health News:Scott Campbell Agency and Nonprofit Stillwaters Cancer Support Services Initiate New Charity Campaign in Waukesha, WI to Provide Help for People Touched by Cancer 3Health News:Say I Do To Surgery: Bridal Beauty On The Rise According to New Survey 2Health News:Say I Do To Surgery: Bridal Beauty On The Rise According to New Survey 3Health News:Orthopedic Surgeon Announces New Pro Bono Prolotherapy and Regenerative Medicine Clinic for Underserved Communities in Los Angeles 2
    ... collaborative team of researchers spearheaded by Dennis Carson M.D., professor ... UCSD Cancer Center at the University of California, San Diego ... a toxic blue-green algae found in the South Pacific. ... paper that will be published online in Proceedings of the ...
    ... leader in radiology and medical image and information management,solutions, today announced it ... ended December 31, 2007, before the,market opens on Friday, February 29, 2008., ... -- Friday, ... -- Call begins promptly at 8:30 a.m. (Eastern Time), 7:30 a.m. ...
    ... Finding could lead to less controversial method of treating ... scientists say they,ve reprogrammed human skin cells into ones ... a breakthrough that could aid in treating many diseases ... the ability to become every cell type found in ...
    ... an Integral Part of MedCath,s Growth Plans, CHARLOTTE, ... and its physician partners today announced plans to double,the ... Antonio, Texas,creating a 120-bed acute care and heart hospital., ... of shelled,space into 60 inpatient beds, which will be ...
    ... of acute coronary events such as heart attack in adults ... Italy, researchers reported in Circulation: Journal of the American Heart ... the city for five years preceding a public smoking ban ... found an 11.2 percent reduction of acute coronary events in ...
    ... physicians specializing in geriatrics, internal or family medicine or ... with heart failure are at risk of dying, new ... to determine whether patients are within six months of ... decisions such as therapeutic approaches and referral for palliative ...
    Cached Medicine News:Health News:UCSD research team identifies novel anticancer drug from the sea 2Health News:AMICAS Schedules Fourth Quarter and 2007 Year End Earnings Results Conference Call 2Health News:Scientists Reprogram Human Skin Cells Into Embryonic Stem Cells 2Health News:Scientists Reprogram Human Skin Cells Into Embryonic Stem Cells 3Health News:MedCath Plans 60-bed Expansion at TexSAn Heart Hospital 2Health News:MedCath Plans 60-bed Expansion at TexSAn Heart Hospital 3Health News:Acute coronary events decreased after public smoking ban in Italy 2Health News:Acute coronary events decreased after public smoking ban in Italy 3Health News:Doctors uncertain about approaches to care for heart failure patients, SLU study finds 2
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: